{"product_id":"tcmd-bcg-matrix","title":"(TCMD) Tactile Systems Technology, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Tactile Systems Technology, Inc. BCG Matrix is a company-specific strategy tool that helps you see how its products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. It is used for portfolio review, investment planning, and strategic decision-making, and this page already shows a real preview of the actual analysis. Buy the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlexitouch Plus: 1 flagship device\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlexitouch Plus is Tactile Systems Technology, Inc.’s core pneumatic compression platform for lymphedema and the center of its U.S. direct-sales model. It drives most of the company’s recurring home-care demand, making it the main revenue engine. With home treatment still gaining share versus clinic-based care, Flexitouch Plus is the clearest Star in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLymphedema: core growth market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLymphedema is Tactile Systems Technology, Inc.’s core growth market, with 2024 net revenue of about $310 million and continued gains from its home-use Flexitouch Plus platform. Demand is supported by more cancer survivorship, better diagnosis, and a clear shift away from clinic-based care. With lymphedema affecting up to 1 in 5 breast cancer survivors, unmet need still supports device adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpper extremity: breast-cancer linked\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpper-extremity products are a Star because breast-cancer related lymphedema drives the biggest and most durable referral flow. The segment benefits from clear physician pathways, strong clinical need, and repeat use, which supports premium pricing and patient reorders. That makes it one of Tactile Systems Technology, Inc.'s most defensible growth engines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLower extremity: large edema pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLower-extremity disease is a big, recurring pool for Tactile Systems Technology, Inc.; lymphedema affects about 3 million Americans, and chronic cases often need long-term home compression. That makes this a clear volume lever, since deeper penetration can grow recurring use without a brand-new product launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, chronic patient pool\u003c\/li\u003e\n\u003cli\u003eHome compression fits recurring care\u003c\/li\u003e\n\u003cli\u003ePenetration can lift volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHead and neck: specialty configuration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHead and neck specialty configs sit in a narrow niche with few direct rivals, and they address post-cancer lymphedema care, a need that grows as survivorship rates improve. Tactile Systems Technology reported about $315 million in annual revenue, so even modest uptake here can add meaningful scale. If adoption keeps rising, this niche can shift from star to cash-cow economics through repeat use and lower selling friction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew direct competitors\u003c\/li\u003e\n\u003cli\u003ePost-cancer care demand is growing\u003c\/li\u003e\n\u003cli\u003eRevenue base is already sizable\u003c\/li\u003e\n\u003cli\u003eHigher adoption supports cash-cow potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlexitouch Plus Powers Tactile’s Home-Care Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFlexitouch Plus remains Tactile Systems Technology, Inc.’s Star: home-based lymphedema care, direct sales, and recurring use support growth. 2024 net revenue was about $310 million, and upper-extremity demand stays strong as breast-cancer related lymphedema drives referrals. Lower-extremity and head-and-neck niches add durable, repeat-use volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $310 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain platform\u003c\/td\u003e\n\u003ctd\u003eFlexitouch Plus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore demand\u003c\/td\u003e\n\u003ctd\u003eUpper-extremity lymphedema\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth tailwind\u003c\/td\u003e\n\u003ctd\u003eHome care shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTactile Systems Technology BCG Matrix maps its products into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or exit decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix for Tactile Systems Technology, Inc., highlighting growth and cash cows to simplify strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTactile Systems Technology, Inc. Reference Sources provide a credible trail that speeds diligence and supports better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntre: 1 portable home system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntre is Tactile Medical’s portable home pneumatic compression system for venous disease and lymphedema, so it fits the Cash Cows box: mature, well known, and less launch-heavy than newer bets. Tactile Systems Technology, Inc. has built a recurring home-therapy base around this category, which supports steady revenue and lower go-to-market spend. Its value comes from retention and repeat use, not fast new-user expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic venous insufficiency: mature care lane\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic venous insufficiency is Tactile Systems Technology, Inc.’s mature, reimbursement-led cash cow: the U.S. affects about 10% to 30% of adults, but growth is slower than newer lymphedema use cases. Recurring treatment needs support steadier demand and lower sales volatility. \u003c\/p\u003e\n\u003cp\u003eThat makes CVI a stable revenue lane, not the main growth engine. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVenous leg ulcers: ongoing wound care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVenous leg ulcers are a defined wound-care adjacent niche for Tactile Systems Technology, Inc., and they fit Cash Cows because patients often need repeated compression and long follow-up. That steady use can support recurring revenue and solid margins, even if growth is slower than faster-moving categories. The market is not explosive, but its repeat care pattern can help generate dependable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReplacement garments: repeat sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompression garments and related supplies turn Tactile Systems Technology, Inc.’s installed base into repeat sales, because patients need ongoing replacements after initial device use. This is classic cash-cow behavior: slower growth, but sticky demand and better lifetime value per patient. The company’s recurring supply mix helps monetize each therapy account beyond the first device sale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys lift customer lifetime value.\u003c\/li\u003e\n\u003cli\u003eDemand is steadier than device launches.\u003c\/li\u003e\n\u003cli\u003eSupply revenue supports cash flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement operations: payer engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTactile Systems Technology, Inc.’s reimbursement operations are a built payer engine: prior authorization and payer support reduce sales friction for mature therapy products and help close more orders at scale. This is a support asset, not a growth bet, because it protects conversion and repeat use rather than driving new product demand. In BCG terms, it acts like a cash cow by smoothing revenue capture from an established base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower prior-auth friction\u003c\/li\u003e\n\u003cli\u003eSupports higher conversion\u003c\/li\u003e\n\u003cli\u003eProtects mature-product sales\u003c\/li\u003e\n\u003cli\u003eDrives cash, not rapid growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTactile’s Cash Cows: Recurring Demand, Steady Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows at Tactile Systems Technology, Inc. are the mature, repeat-use lanes: Entre, CVI, venous leg ulcers, garments, and reimbursement support. These businesses lean on recurring therapy use and replacements, so they throw off steadier cash than newer growth bets. U.S. CVI affects about 10% to 30% of adults, which supports durable demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntre\u003c\/td\u003e\n\u003ctd\u003eInstalled base, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVI\u003c\/td\u003e\n\u003ctd\u003e10% to 30% adult prevalence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGarments\u003c\/td\u003e\n\u003ctd\u003eOngoing replacement sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eTactile Systems Technology, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Tactile Systems Technology, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No hidden edits, no sample pages—just the complete, ready-to-use report. Download the full file instantly and put it to work for analysis, presentations, or strategic planning. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo major divestiture candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic filings do not show a large standalone unit that fits a classic dog; Tactile Systems Technology, Inc. still relies on 3 core device lines: Flexitouch Plus, Entre Plus, and AffloVest. Revenue remains concentrated in these franchises, so there is no obvious low-share, low-growth business to sell. At end-2025, the dog bucket looks small, and likely near zero.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-U.S. footprint: limited scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTactile Systems Technology, Inc. remains heavily U.S.-focused, with international sales still a small part of the mix. That limited non-U.S. footprint means the company has little geographic scale outside its core market, so overseas activity does not read as a growth leader in the Dogs quadrant. In 2024, its business model was still driven by domestic clinical and reimbursement channels, not broad global reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash-pay orders: volatile demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCash-pay orders are usually smaller, more erratic, and harder to scale than reimbursed care. For Tactile Systems Technology, Inc., that makes this channel weaker than payer-backed volume, since it depends more on consumer timing than clinical coverage. In BCG terms, volatile demand plus lower efficiency points to a Dog-like profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume legacy configurations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-volume legacy configurations at Tactile Systems Technology, Inc. are Dogs in BCG terms: they tie up support and service effort but are unlikely to move company-wide growth. The core Flexitouch Plus platform remains the main growth engine, so older niche setups should be treated as maintenance items, not priority capital.\u003c\/p\u003e\n\u003cp\u003eThat fit matters in FY2025 because management focus and spending should stay on higher-return devices and channels, not small legacy lines. The clean read is simple: protect service, limit new investment, and let the core platform carry the business.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low strategic value\u003c\/li\u003e\n\u003cli\u003eSupport only, no expansion spend\u003c\/li\u003e\n\u003cli\u003eFlexitouch Plus dominates the mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric compression substitutes: low moat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneric compression substitutes stay dog-like because they face heavy price pressure and weak differentiation, while Tactile Medical’s proprietary systems keep the clinical moat. In Tactile Medical’s latest filings, revenue is still driven by its branded therapy platform, not simple compression products, so low share and low growth make these substitutes a poor BCG fit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow price, low differentiation\u003c\/li\u003e\n\u003cli\u003eNo proprietary clinical moat\u003c\/li\u003e\n\u003cli\u003eSmall share, weak growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTactile’s FY2025 Dogs Are Nearly Zero\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTactile Systems Technology, Inc.’s Dogs bucket is near zero in FY2025. No standalone low-share, low-growth unit is visible; revenue still centers on Flexitouch Plus, Entre Plus, and AffloVest.\u003c\/p\u003e\n\u003cp\u003eSmall legacy setups and cash-pay orders look Dog-like because they add support load but little scale. International sales also stay minor, so they do not justify new spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eFY2025 read\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy niches\u003c\/td\u003e\n\u003ctd\u003eLow volume\u003c\/td\u003e\n\u003ctd\u003eSupport only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash-pay orders\u003c\/td\u003e\n\u003ctd\u003eSmaller, erratic\u003c\/td\u003e\n\u003ctd\u003eWeak growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-U.S. sales\u003c\/td\u003e\n\u003ctd\u003eSmall mix\u003c\/td\u003e\n\u003ctd\u003eNo scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffloVest: 2022 acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAffloVest, acquired in 2022, broadens Tactile Systems Technology, Inc. into airway clearance and adds a new therapeutic area beyond lymphedema. Tactile Systems Technology, Inc. reported about $305 million in 2024 revenue, but AffloVest is still a much smaller franchise. That mix of new growth potential and low relative share fits a question mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBronchiectasis: underpenetrated market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBronchiectasis remains underpenetrated: U.S. prevalence is estimated at roughly 500,000 adults, yet many cases are still missed or diagnosed late. That leaves room for Tactile Systems Technology, Inc. to grow airway-clearance use as awareness and CT-based diagnosis improve. The upside is real, but durable share gains still need proof in prescribing and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCystic fibrosis: specialty respiratory care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCystic fibrosis care is well known and guided by clear standards, but Tactile Systems Technology, Inc. is not the category leader in this niche, so it fits better as a Question Mark than a Star. The Cystic Fibrosis Foundation said about 40,000 people in the United States live with CF, and specialty airway clearance remains a meaningful but focused market. That makes the segment attractive, yet still too small and contested for dominant share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuromuscular disorders: niche demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuromuscular disorders are a niche demand pool for Tactile Systems Technology, Inc.: patients often need secretion management for years, but the reachable base is far smaller than lymphedema. ALS prevalence is about 5 per 100,000 in the U.S., so the clinical need is real, yet the franchise scale is limited. That makes this a classic invest-or-trim call.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClear unmet need\u003c\/li\u003e\n\u003cli\u003eLong treatment duration\u003c\/li\u003e\n\u003cli\u003eNarrow addressable market\u003c\/li\u003e\n\u003cli\u003eLower scale than lymphedema\u003c\/li\u003e\n\u003cli\u003eBest as selective capital use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAirway-clearance expansion: growth bet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHome airway-clearance has real upside: the U.S. had about 61 million people age 65+ in 2024, and COPD still affects about 16 million Americans. Tactile Medical already has the therapy platform, but adoption is still early, so this sits in a question-mark bucket rather than a star. If payer coverage and clinician use keep rising, the segment can scale fast. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig need, growing patient base\u003c\/li\u003e\n\u003cli\u003eTactile Medical has a foothold\u003c\/li\u003e\n\u003cli\u003eScale is not yet proven\u003c\/li\u003e\n\u003cli\u003eFaster adoption could lift it\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffloVest and Airway Niches: Real Demand, Small Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Tactile Systems Technology, Inc. are AffloVest and other airway-clearance niches: they have real demand, but small share and no category lead. Tactile Systems Technology, Inc. posted about $305 million revenue in 2024, while the U.S. has about 500,000 adults with bronchiectasis and about 40,000 people with cystic fibrosis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eWhy it is a Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAffloVest\u003c\/td\u003e\n\u003ctd\u003eSmall share\u003c\/td\u003e\n\u003ctd\u003eGrowth potential, not dominant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBronchiectasis\u003c\/td\u003e\n\u003ctd\u003e~500,000 adults\u003c\/td\u003e\n\u003ctd\u003eUnderdiagnosed, early adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003ctd\u003e~40,000 U.S. patients\u003c\/td\u003e\n\u003ctd\u003eFocused, contested niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235089883401,"sku":"tcmd-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tcmd-bcg-matrix.webp?v=1785733260","url":"https:\/\/dcfanalyst.com\/products\/tcmd-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}